The ACR recently had an opportunity to speak with Anthem leadership to follow up on concerns about specialty pharmacy acquisition mandates being implemented by Anthem plans in California and New York. Anthem clarified that they do not expect these mandates to impact community-based providers. Beginning in December 2020, Anthem plans in certain states will require…
Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020
In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:
Anti-TNF Treatment Trial Encouraging for High-Risk APS Pregnancies
Early results in a phase 2 trial are finding that adding a TNF blocker to other treatment could greatly lower the risk of serious complications during pregnancy for women who have antiphospholipid syndrome with lupus anticoagulant.
Racial Disparities Persist in OA & RA Management
From pain management to arthroplasty, African American patients with OA and RA experience worse outcomes than white patients. But the reasons for these health disparities are difficult to parse from socioeconomic and cultural factors.
Chikungunya Virus May Lead to Long-Term Joint Pain
COVID-19 isn’t the only viral infection on the rise across the globe, so is chikungunya, which can cause arthritis-like symptoms and may lead to long-term joint pain.
Optimize Gout Management with the Latest Evidence-Based Guidance
ACR Convergence 2020—In May 2020, the ACR published its updated guideline for the management of gout.1 It followed on the heels of a 2017 gout guideline published by the American College of Physicians.2 Although the guidelines provide similar recommendations on the treatment of acute gout, they differ importantly in the use of uric acid-lowering therapy…
Fellowship Recruitment Goes Virtual in 2020: A Conversation with 3 Fellowship Program Directors
The desire for safety during the COVID-19 pandemic has forced rheumatology fellowship programs to embrace virtual platforms. Here are some insights into how this change has affected recruitment in 2020.
Synopsis: Single Cell Technologies & New Insights into SLE
ACR CONVERGENCE 2020—The definition of cell type depends increasingly on a cell’s molecular features. On Friday, Nov. 6, 2020, Alex Kuo, PhD, senior scientist at Stanford University School of Medicine, Stanford, Calif., described six technologies that are relatively mature and can be used for rheumatic disease research: Rapidly developing single-cell RNA sequencing (scRNA-seq); Cellular indexing…
Upadacitinib Safety Similar to Other Jakinibs for RA
(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest. Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized…
Investigation Continues on Repurposed Rheumatology Therapies for COVID-19 Cytokine Storm
Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.
- « Previous Page
- 1
- …
- 172
- 173
- 174
- 175
- 176
- …
- 816
- Next Page »